Poster Session

Session Chairs

Karine Sargsyan, Managing Director for Internationa Biobanking and Education (Medical University of Graz)

Annelies Debucquoy, National Node Director (BBMRI.be - Belgian Cancer Registry)

Speakers and Presentations  

• Constantinos Deltas, Professor of Genetics (University of Cyprus) -PO-08 "Antibody response to SARS-CoV-2 in the Cypriot population"  
• Anna Michalska-Falkowska, Post Doc Researcher (Medical University of Bialystok) - PO-05 "Partnership between University and Industry as a trigger for the implementation of precision oncology into clinical practice"  
• Constantinos Deltas, Professor of Genetics (University of Cyprus) - PO-04 "A Biobank is growing in Cyprus"  
• Sylwia Knap, Laboratory Diagnostician (Regional Science and Technology Center) - PO-18 "Assessment of vitamin D concentration in blood, among inhabitants of the Świętokrzyskie voivodeship"  
• Denis Marino, Deputy Director (University of Geneva) - PO-61 "Bahop Biobank in Paediatric Haematology and Oncology: What's new after a 5-year journey?"  
• Ellen Rebecca Kruuse, Medical Student (University of Tartu, Institute of Genomics) - PO-78 "Extended phenotype studies in carriers and potentially affected individuals of selected lysosomal storage diseases among the participants of the Estonian Biobank"  
• Caitlin Ahern, Communications Officer (BBMRI-ERIC) - PO-93 "The BBMRI-ERIC ELSI Knowledge Base 2.0: hot topics, challenges and solutions"

Session Information

There are more than 350 registered biobanks in the BBMRI-ERIC registry in Europe alone (7), and even more worldwide (8). Some are well known, to the point that every researcher in the field hasat least heard of them, while others are less well known. Nevertheless, the productivity and success of biobanks is measured very differently in different biobanks and different settings. On the one hand, the different generations and types of biobanks and biorepositories present wellknown challenges, especially when it comes to keeping up with technological advances and adapting design with restricted funds (e.g. infrastructure decisions, predicting the correct collection strategy for the future, data volume and the type of collection, etc.). On the other hand, key KSFs are dependent on the setting of the biobank, but there is an overlap of main nucleus of success perception and/or measurement by biobanks themselves.

In this Poster Session you will have the opportunity to listen to a selection of Poster related to the following topics, and you will have the opportunity to ask questions to the Poster Presenters.:

- Biobanking in Personalized Medicine

- Paediatric Biobanking

- Rare disease collections – The Treasures of the Biobanks